RJA
YCBD icon

Raymond James & Associates’s cbdMD YCBD Stock Holding History

Raymond James & Associates’s Portfolio YCBD Stock Details YCBD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-104
Closed -$166K – 3766
2019
Q1 		$166K Hold
104
– – ﹤0.01% 3298
2018
Q4 		$116K Buy
+104
New +$148K ﹤0.01% 3281

Other funds holding YCBD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's YCBD Position: Q2 2019 in Review

Raymond James & Associates sold out of cbdMD (YCBD) in Q2 2019, closing a stake of 104 shares — an estimated $166K sold.

Raymond James & Associates first reported a position in YCBD in Q4 2018 and held it in 2 quarters. The position peaked at $166K in Q1 2019. 35 funds tracked by Wall St. Rank hold YCBD as of Q2 2019.

  • Raymond James & Associates reported no remaining cbdMD position as of Q2 2019 after selling out during the quarter.
  • Raymond James & Associates sold 104 cbdMD shares in Q2 2019, an estimated $166K.
  • Raymond James & Associates first reported a position in cbdMD in Q4 2018 and held it in 2 quarters.
  • Raymond James & Associates's cbdMD position peaked at $166K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held cbdMD as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.